SAN DIEGO, December 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Steve Zaniboni (CFO) for an update on selectION’s clinical work in atopic dermatitis.
Site Search
Recent News
- BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis
- selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
- Meet selectION, Inc. at the BIO International Convention in Boston, on June 5th to 8th, 2023